Abstract
GABAA receptor channels are ubiquitous in the mammalian central nervous system mediating fast inhibitory neurotransmission by becoming permeant to chloride ions in response to GABA. The emphasis of this review is on the rich chemical diversity of ligands that influence GABAA receptor function. Such diversity provides many avenues for the design and development of new chemical entities acting on GABAA receptors. There is also a significant diversity of GABAA receptor subtypes composed of different protein subunits. The discovery of subtype specific agents is a major challenge in the continuing development of GABAA receptor pharmacology. Leads for the discovery of new chemical entities that influence GABAA receptors come from using recombinant GABAA receptors of known subunit composition as has been elegantly demonstrated by the refining of benzodiazepine actions with a1 subunit preferring agents showing sedative properties but not anxiolytic properties. The most recent advances in the therapeutic use of agents acting on GABAA receptors concern the promotion of sound sleep. Many herbal medicines are used to promote sleep and many of their active ingredients include flavonoids and terpenoids known to modulate GABAA receptor function.
Keywords: inhibitory neurotransmitter, ligand-gated ion channels, second membrane-spanning domain (m), schizophrenia, epilepsies, sleep disorders, anxiolytic, benzodiazepines, spatial memory, ethanol
Current Pharmaceutical Design
Title: GABAA Receptor Channel Pharmacology
Volume: 11 Issue: 15
Author(s): Graham A.R. Johnston
Affiliation:
Keywords: inhibitory neurotransmitter, ligand-gated ion channels, second membrane-spanning domain (m), schizophrenia, epilepsies, sleep disorders, anxiolytic, benzodiazepines, spatial memory, ethanol
Abstract: GABAA receptor channels are ubiquitous in the mammalian central nervous system mediating fast inhibitory neurotransmission by becoming permeant to chloride ions in response to GABA. The emphasis of this review is on the rich chemical diversity of ligands that influence GABAA receptor function. Such diversity provides many avenues for the design and development of new chemical entities acting on GABAA receptors. There is also a significant diversity of GABAA receptor subtypes composed of different protein subunits. The discovery of subtype specific agents is a major challenge in the continuing development of GABAA receptor pharmacology. Leads for the discovery of new chemical entities that influence GABAA receptors come from using recombinant GABAA receptors of known subunit composition as has been elegantly demonstrated by the refining of benzodiazepine actions with a1 subunit preferring agents showing sedative properties but not anxiolytic properties. The most recent advances in the therapeutic use of agents acting on GABAA receptors concern the promotion of sound sleep. Many herbal medicines are used to promote sleep and many of their active ingredients include flavonoids and terpenoids known to modulate GABAA receptor function.
Export Options
About this article
Cite this article as:
Johnston A.R. Graham, GABAA Receptor Channel Pharmacology, Current Pharmaceutical Design 2005; 11 (15) . https://dx.doi.org/10.2174/1381612054021024
DOI https://dx.doi.org/10.2174/1381612054021024 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Natural Compounds for the Prevention and Treatment of Nonalcoholic
Fatty Liver Disease: A Review on Molecular Mechanisms
Current Molecular Pharmacology Examination of Hippocampal Differences Between Alzheimer Disease, Amnestic Mild Cognitive Impairment and Normal Aging: Diffusion Kurtosis
Current Alzheimer Research Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Current Pharmaceutical Design The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography
Current Drug Targets Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Current Signal Transduction Therapy The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
Current Pharmaceutical Design Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal The Role of ABC and SLC Transporters in the Pharmacokinetics of Dietary and Herbal Phytochemicals and their Interactions with Xenobiotics
Current Drug Metabolism Discovery of Substituted N-(6-Chloro-3-cyano-4-phenyl-4H-chromen-2-yl)- 2-(4-chloro-phenoxy)-acetamide for Biphasic Anticancer and Anticonvulsant Activities
Medicinal Chemistry Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Monocyclic and Fused Azines and Azoles as Histamine H<sub>4</sub> Receptor Ligands
Current Medicinal Chemistry Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research Epilepsy, Regulation of Brain Energy Metabolism and Neurotransmission
Current Medicinal Chemistry Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology Gene Therapy Repairs for the Epileptic Brain: Potential for Treatment and Future Directions
Current Gene Therapy Recent Advancement in Computer-Aided Drug Design
Current Pharmaceutical Design